At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $469.31, down -2.66%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ALNY shares have gain 4.89% over the last week, with a monthly amount glided 7.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on August 04, 2025, when Wolfe Research upgraded its rating to a Peer Perform. Previously, Oppenheimer upgraded its rating to Outperform on August 04, 2025, and kept the price target unchanged to $490. Truist started tracking the stock assigning a Buy rating and suggested a price target of $385 on July 21, 2025. Redburn Atlantic initiated its recommendation with a Buy and recommended $353 as its price target on March 31, 2025. JP Morgan upgraded its rating to Overweight for this stock on March 24, 2025, and upped its price target to $328. In a note dated November 12, 2024, Wolfe Research downgraded an Underperform rating on this stock.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $205.87 and $484.21. Currently, Wall Street analysts expect the stock to reach $390.75 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $469.31 at the most recent close of the market. An investor can expect a potential drop of -16.74% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.46B for trailing twelve months, which represents an 17.26% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -2.74 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 460.51 points at the first support level, and at 451.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 479.08, and for the 2nd resistance point, it is at 488.85.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 2.80. Further, the Quick Ratio stands at 2.75, while the Cash Ratio is 0.86. Considering the valuation of this stock, the price to sales ratio is 24.99, the price to book ratio is 245.30.
Transactions by insiders
Recent insider trading involved Reitan Colleen F, Director, that happened on Sep 09 ’25 when 18000.0 shares were purchased. EVP, Chief Commercial Officer, Tanguler Tolga completed a deal on Aug 29 ’25 to sell 3474.0 shares. Meanwhile, Officer Tanguler Tolga bought 3474.0 shares on Aug 29 ’25.
